Yumanity Therapeutics

Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award winning protein folding expert, Susan Lindquist, Ph.D., and renowned biotech industry leader, Tony Coles, M.D., Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS. Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society. Despite the fact that an estimated 50 million people worldwide suffer from them, there are no approved disease-modifying therapies or cures. Leveraging its three integrated discovery platforms, Yumanity’s new approach to drug discovery and development concentrates on the cell’s characteristics, or phenotype, and the disease pathologies caused by protein misfolding.